Werewolf Therapeutics provided a business update highlighting key milestones for 2025 regarding its clinical development programs. The company is expecting to release data from the Phase 1/1b clinical ...
Werewolf Therapeutics provided a business update, announcing progress in their clinical trials for WTX-124, a conditionally activated therapeutic for cutaneous melanoma, with full enrollment in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback